Paclitaxel (紫杉醇) 是微管聚合稳定剂，IC50是0.1 pM。Paclitaxel 是有丝分裂抑制剂。

>99 %

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

紫杉醇;NSC 125973;Taxol

Lyophilized powder

DMSO：171 mg/mL (200.25 mM)

Ethanol：18 mg/mL (21.07 mM)

Microtubule (human endothelial cells)

Paclitaxel inhibits non-endothelial type human cells at 104 – to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively.

[1] Wang J, et al. Anticancer Drugs. 2003, 14(1), 13-19.
[2] Sun RG, et al. Gen Physiol Biophys. 2012, 31(1), 1-10.
[3] Zhang XH, et al. Cancer Lett. 2012, 322(2), 213-222.
[4] Chang J, et al. Breast Cancer Res Treat. 2012.